Biotech RadarJobs updated

COMPANY

Mirador Therapeutics

HQ: San Diego, CA source · miradortx.com ↗ · West Coast

Clinical Phase 2

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Keywords: Inflammatory Bowel Disease Ulcerative Colitis Crohn's Disease MT-201 MT-501 MT-701 MT-251

6Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: A Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy Participants source ↗
  2. Trial start Phase 1: A First-in-Human Single and Multiple Ascending Dose Study of MT-251 source ↗
  3. Trial start Phase 1: A First-in-Human Single and Multiple Ascending Dose Study of MT-701 source ↗
  4. Trial start Phase 1: A First-in-Human Single and Multiple Ascending Dose Study of MT-201 source ↗
  5. Trial start 2: A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease source ↗
  6. Trial start Phase 1: A First-in-Human Single and Multiple Ascending Dose Study of MT-501 source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 6

RecordTitlePhaseStatusStartPrimary completion
NCT07776782A Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy ParticipantsPhase 1RecruitingJul 16, 2026Nov 12, 2026 (estimated)
NCT07396909A First-in-Human Single and Multiple Ascending Dose Study of MT-701Phase 1CompletedJan 12, 2026Apr 16, 2026 (actual)
NCT07113522A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease2RecruitingJun 26, 2025Apr 30, 2027 (estimated)
NCT07423299A First-in-Human Single and Multiple Ascending Dose Study of MT-251Phase 1RecruitingJan 23, 2026Mar 8, 2027 (estimated)
NCT06762457A First-in-Human Single and Multiple Ascending Dose Study of MT-501Phase 1CompletedDec 11, 2024May 22, 2025 (actual)
NCT07219368A First-in-Human Single and Multiple Ascending Dose Study of MT-201Phase 1RecruitingOct 8, 2025Nov 24, 2026 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback